+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls



Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls



Cancer Research 50(24): 7815-7819



We used an enzyme-linked immunosorbent assay to test sera from 186 cases of invasive cervical cancer and 172 age-matched controls for IgG and IgA antibodies to an human papillomavirus 16 E7 peptide and to peptide 245, representing an epitope in E2. Cases had significantly higher mean absorbance values than controls for both immunoglobulin isotypes to E7 and elevated mean values for IgG to peptide 245. Since absorbances were not normally distributed we analyzed cervical cancer risk for seropositive and seronegative women. Of the traditional cervical cancer risk factors, cigarette smoking, educational level, number of pregnancies, time interval since last Papanicolaou smear, and age at first intercourse influenced the distribution of seropositivity to some of the viral antigens. Adjusting for these variables, the odds ratios of cervical cancer associated with IgG to E7 was 5.28 [95% confidence (95% CI) = 2.4-11.6] and that with IgA to E7 was 2.67 (95% CI = 1.3-5.3). IgG to peptide 245 was less strongly associated, odds ratio 1.68 (95% CI = 1.2-3.3), and IgA to peptide 245 was not significantly associated with disease. These findings suggest that antibodies to E7 are markers for invasive cervical cancer. However, seropositivity correlated poorly with clinical state, survival, or the presence of human papillomavirus DNA in the cancer tissue.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 007609908

Download citation: RISBibTeXText

PMID: 2174733


Related references

Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. Journal of Infectious Diseases 170(6): 1424-1431, 1994

Occurrence of antibodies to L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical cancer patients and controls. International Journal of Cancer 48(5): 682-688, 1991

Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls. Tohoku Journal of Experimental Medicine 170(2): 113-121, 1993

Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. Cancer 74(8): 2307-2313, 1994

Detection of E5 oncoprotein in human papillomavirus type 16-positive cervical scrapes using antibodies raised to synthetic peptides. Journal of General Virology 75: 2451-2456, 1994

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. Journal of Clinical Oncology 15(2): 610-619, 1997

The prevalence of human papillomavirus type 16 and 18 DNA in cervical cancer in different age groups: a study on the incidental cases of cervical cancer in Norway in 1983. Gynecologic Oncology 41(2): 141-148, 1991

Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. Journal of Infectious Diseases 172(1): 19-24, 1995

The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer. Gynecologic Oncology 61(1): 73-78, 1996

Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer. Journal of Virology 74(14): 6632-6636, 2000

The inspection of human papillomavirus type 16 E6,E7 antibodies in human sera with cervical cancer. Xi'an Yike Daxue Xuebao 15(4): 311-313, 1994

Independent association of antibodies against human papillomavirus type 16 E1/E4 and E7 proteins with cervical cancer. Virology 190(2): 724-732, 1992

Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. Journal of Clinical Microbiology 29(8): 1579-1588, 1991

Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. Journal of the National Cancer Institute 81(22): 1698-1704, 1989

Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia. Intervirology 38(3-4): 187-191, 1995